Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth

Cancer Research

Volumn 60, Issue 19, 2000, Pages 5514-5521

  Kjaergaard, J ^a   Tanaka, J ^a   Kim, J A ^a   Rothchild, K ^a   Weinberg, A ^a   Shu, S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL SURFACE PROTEIN; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; OX 40 RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; GLIOMA; HISTOLOGY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; BRAIN NEOPLASMS; FEMALE; GLIOMA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0034306979     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. The two-signal model of lymphocyte activation twenty-one years later
2. Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy
3. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
4. Transplantation
5. CD28/B7 system of T cell costimulation
6. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
7. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
8. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells
9. Accessory molecule and costimulation requirements for CD4 T cell response
10. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene
11. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum
12. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12
13. The role of CD40 in the regulation of humoral and cell-mediated immunity
14. The role of CD40 ligand in costimulation and T-cell activation
15. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
16. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood
17. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
18. Role of 4-1BB in immune responses
19. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
20. Antigens of activated rat T lymphocytes including a molecule of 50.000 Mr detected only on CD4 positive T blasts
21. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis
22. + spinal cord T cells of Lewis rats with EAE
23. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis
24. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers
25. Engagement of the OX-40 receptor in vivo enhances antitumor immunity
26. Purification of L-selectine(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
27. Adoptive immunotherapy of newly induced murine sarcomas
28. The selection and characterization of an invasive variant of the B16 melanoma
29. Studies of the chemotherapy of experimental brain tumors: Development of an experimental model
30. OX-40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX-40 ligand
31. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells
32. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
33. Expression of the T cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease
34. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis
35. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein
36. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand
37. Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE
38. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues
39. Adult human glial cells can present target antigens to HLA-restricted cytotoxic T-cells
40. Role of central nervous system microvascular pericytes in activation of antigen-primed splenic T-lymphocytes
41. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma
42. Cellular immune responsiveness of patients with primary intracranial tumors
43. Lymphocytic infiltrates in primary glio-blastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases
44. + T cells against the wild-type tumor: Correlation with antigen presentation capability
45. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
46. Molecular characterization of murine and human OX-40/OX-40 ligand systems: Identification of a human OX-40 ligand as the HTLV-1-regulated protein gp34
47. OX-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T celt responses
48. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis
49. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion
50. + T cells into high IL-4-producing effectors
51. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulate expression of the chemokine receptor, Blr-1
52. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
53. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody
54. + T cells: A common basis between tumor immunity and autoimmunity